N-Butyldeoxynojirimycin
|
|
|
- CAS-Nr.
- 72599-27-0
- Englisch Name:
- N-Butyldeoxynojirimycin
- Synonyma:
- nb-dnj;Zavesca;OGT 918;megasat;SC-48334;Mg gross;miglusta;N-Butylmoranoline;N-BUTYLDEOXYNOJIRIMYCIN;N-BUTYL-1-DEOXYNOJIRIMYCIN
- CBNumber:
- CB0125257
- Summenformel:
- C10H21NO4
- Molgewicht:
- 219.28
- MOL-Datei:
- 72599-27-0.mol
|
N-Butyldeoxynojirimycin Eigenschaften
- Schmelzpunkt:
- 126-127℃
- alpha
- D25 -15.9° (c = 0.77 in water)
- Siedepunkt:
- 394.7±42.0 °C(Predicted)
- Dichte
- 1.234
- RTECS-Nr.
- TN4350150
- storage temp.
- 2-8°C
- Löslichkeit
- DMSO 44 mg/mL (200.66 mM) Ethanol 22 mg/mL (100.33 mM) Water 44 mg/mL (200.66 mM)
- Aggregatzustand
- Powder
- pka
- 13.72±0.70(Predicted)
- Farbe
- White
- Wasserlöslichkeit
- Soluble in water at 10mg/ml
- InChI
- InChI=1S/C10H21NO4/c1-2-3-4-11-5-8(13)10(15)9(14)7(11)6-12/h7-10,12-15H,2-6H2,1H3/t7-,8+,9-,10-/m1/s1
- InChIKey
- UQRORFVVSGFNRO-UTINFBMNSA-N
- SMILES
- N1(CCCC)C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO
Sicherheit
- Risiko- und Sicherheitserklärung
- Gefahreninformationscode (GHS)
| WGK Germany |
3 |
|
|
| HS Code |
2933399990 |
|
|
| Bildanzeige (GHS) |
|
| Alarmwort |
Warnung |
| Gefahrenhinweise |
| Code |
Gefahrenhinweise |
Gefahrenklasse |
Abteilung |
Alarmwort |
Symbol |
P-Code |
| H315 |
Verursacht Hautreizungen. |
Hautreizung |
Kategorie 2 |
Warnung |
![GHS hazard pictograms]() src="/GHS07.jpg" width="20" height="20" /> |
P264, P280, P302+P352, P321,P332+P313, P362 |
| H319 |
Verursacht schwere Augenreizung. |
Schwere Augenreizung |
Kategorie 2 |
Warnung |
![GHS hazard pictograms]() src="/GHS07.jpg" width="20" height="20" /> |
P264, P280, P305+P351+P338,P337+P313P |
|
| Sicherheit |
| P264 |
Nach Gebrauch gründlich waschen. |
| P264 |
Nach Gebrauch gründlich waschen. |
| P280 |
Schutzhandschuhe/Schutzkleidung/Augenschutz tragen. |
| P302+P352 |
BEI BERÜHRUNG MIT DER HAUT: Mit viel Wasser/... (Hersteller kann, falls zweckmäßig, ein Reinigungsmittel angeben oder, wenn Wasser eindeutig ungeeignet ist, ein alternatives Mittel empfehlen) waschen. |
| P305+P351+P338 |
BEI KONTAKT MIT DEN AUGEN: Einige Minuten lang behutsam mit Wasser spülen. Eventuell vorhandene Kontaktlinsen nach Möglichkeit entfernen. Weiter spülen. |
| P332+P313 |
Bei Hautreizung: Ärztlichen Rat einholen/ärztliche Hilfe hinzuziehen. |
| P337+P313 |
Bei anhaltender Augenreizung: Ärztlichen Rat einholen/ärztliche Hilfe hinzuziehen. |
|
N-Butyldeoxynojirimycin Chemische Eigenschaften,Einsatz,Produktion Methoden
Beschreibung
Miglustat is an N-alkylated iminosugar, launched as an oral treatment for mild to
moderate type 1 Gaucher’s disease in adult patients for whom enzyme replacement
therapy is not a therapeutic option. It is readily synthesized from D-glucose in three steps by first converting to N-butylglucamine via reductive amination with
butylamine, followed by a microbial oxidation to an aminofuranose intermediate
and subsequent reductive cyclization. Type 1 Gaucher’s disease is a metabolic
disorder caused by the lysosomal accumulation of certain glycosphingolipids (GSLs)
as a result of deficiency in their degradation. Enlargement of the liver and spleen,
low blood platelet and bone lesions are among the key symptoms of this disease.
Miglustat acts by inhibiting glucosylceramide synthase, a glucosyl transferase
enzyme in the biosynthesis of most GSLs, which results in the lowering of GSLs to
a level that can be effectively cleared. Up to 50% reduction in liver and splenocyte
GSL levels are achieved in mice by long-term administration of Miglustat (600–
1800 mg/kg/day for 118 days). Miglustat, dosed at 50 and 100 mg in Gaucher
patients, exhibits dose proportionate pharmacokinetics (t
max=2.5 h, t
1/2=6 to 7 h)
and ＞90% oral bioavailability. Steady-state plasma levels are reached after 4–6
weeks of treatment. Miglustat is not significantly metabolized in humans and the
major route of excretion is renal. In clinical trials, efficacy was demonstrated by
significant reductions in liver and spleen volumes (12 and 19%, respectively) at 12
months and increase in hemoglobin and platelet count (0.91 g/dL and 13.6×10
9/l,
respectively) at 24 months. Miglustat is generally well tolerated by patients and the
most common side effects are diarrhea and weight loss.
Verwenden
Treatment of glycolipid storage diseases.
Definition
ChEBI: A hydroxypiperidine that is deoxynojirimycin in which the amino hydrogen is replaced by a butyl group.
Indications
N-butyldeoxynojirimycin is an approved drug for Niemann–Pick disease type C and Gaucher disease type 1, which are lipid storage disorders[1].
Allgemeine Beschreibung
N-Butyldeoxynojirimycin is an alkylated product of imino sugar deoxynojirimycin.
Biologische Aktivität
Orally active α -glucosidase I and II and ceramide-specific glycosyltransferase inhibitor. Rescues trafficking-deficient F508del-CTFR in human airway epithelial cells via inhibition of ER α -glucosidases I and II. Also has broad spectrum antiviral activity.
N-Butyldeoxynojirimycin Upstream-Materialien And Downstream Produkte
Upstream-Materialien
Downstream Produkte
N-Butyldeoxynojirimycin Anbieter Lieferant Produzent Hersteller Vertrieb Händler.
Global( 135)Lieferanten
- N-BUTYLDEOXYNOJIRIMYCIN
- N-BUTYL-1-DEOXYNOJIRIMYCIN
- (2R)-1-Butyl-2α-(hydroxymethyl)piperidine-3β,4α,5β-triol
- 1,5-(Butylimino)-1,5-dideoxy-D-glucitol
- 1-Butyl-2α-(hydroxymethyl)piperidine-3β,4α,5β-triol
- 1-Butyl-3β,4α,5β-trihydroxypiperidine-2α-methanol
- SC-48334
- (2R,3R,4R,5S)-1-Butyl-2-(hydroxymethyl)-3,4,5-piperidinetriol
- N-Butylmoranoline
- OGT 918
- Zavesca
- nb-dnj
- Miglustat, NB-DNJ, (2R,3R,4R,5S)-1-butyl-2-(hydroxymethyl)piperidine-3,4,5-triol
- N-(n-Butyl)-1-deoxynojirimycin min. 99%
- N-Butyldeoxynojirimycin, Hydrochloride - CAS 72599-27-0 - Calbiochem
- Mg gross
- N-BUTYLDEOXYNOJIRIMYCIN;SC-48334;NB-DNJ;OGT-918
- MIGLUSTAT;N-BUTYLDEOXYNOJIRIMYCIN;NB-DNJ;OGT918
- Miglustat (N-Butyldeoxynojirimycin)
- N-(n-Butyl)-1-deoxynojirimycin
- 3,4,5-Piperidinetriol, 1-butyl-2-(hydroxymethyl)-, (2R,3R,4R,5S)-
- Hot Sale 3, 4, 5-Piperidinetriol, 1-Butyl-2- (hydroxymethyl) -, (2R, 3R, 4R, 5S) N-BUTYLDEOXYNOJIRIMYCIN
- Miglustat hydrochloride salt
- MiglustatQ: What is
Miglustat Q: What is the CAS Number of
Miglustat Q: What is the storage condition of
Miglustat
- oral,Miglustat,Inhibitor,inhibit,ceramide glucosyltransferase,OGT-918,OGT 918,type I gaucher disease
- miglusta
- megasat
- 72599-27-0
- C10H22NO4
- Glucosidase, alpha-
- D to K
- Enzyme Inhibitors
- Enzymes, Inhibitors, and Substrates
- Enzyme Inhibitors by Enzyme
- Biochemicals and Reagents
- BioChemical
- API
